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1. Introduction 
Three recessive mutations in mice result in grossly 
defective mye~ination in the central nervous system 
(CNS) while myelination of peripheral nerves is normal. 
Two of these mutants, the Jimpy (jp) and a myelin 
synthesis deficient mutation (msd) are sex-linked and 
may be alleles [ 1,2] , whereas the third one, the 
Quaking (qk) is autosomai recessive. Brain cerebrosides 
and sulphatides are greatly reduced in all three 
mutants f2-51 . Moreover, a deficiency in the glyco- 
syl-transferases involved in the biosynthesis of cere- 
brosides has now been shown in the Jimpy [6,7 ] , 
Quaking [7,8] and msd ]9] mice. Sulphatide syn- 
thesis also appeared to be altered since there was 
reduced incorporation of ‘“C-galactose into this lipid 
17, IO]. However this type of study does not distin- 
guish between the possibility that sulphatide biosyn- 
thesis is decreased because the precursor cerebrosides 
are greatly reduced, and the possibility that the activity 
of the 3’-phosphoadenosine-5’.phosphosulphate- 
cerebroside suiphotransferase (PAPS-CST), responsible 
for synthesizing sulphatides from cerebrosides, is de- 
pressed. The results presented show that in the three 
mutants, when compared to normal animals, the 
PAPS-CST activities in the brains were greatly 
reduced while they were unchanged in the kidneys. 
* Attach6 de Recherche zi I’INSERM. This work will be part 
of his Thesis of “Doctorat d’Etat”. 
Abbreviations: 
msd : myeiin synthesis deficiency; 
PAPS-CST: 3’-phosphoadenosine-S-phosphosulphate- 
cerebroside-sulphotransferase; 
CNS : centrat nervous system. 
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A preliminary communication concerning Jimpy and 
Quaking mutants has been presented previously [ 1 l] . 
Since then, a paper has been published [ 121 demon- 
strating that the incorporation of 35S-sulphate into 
sulphatides was impaired in the brain of the Jimpy 
mutant, but remained normal in the sciatic nerve. 
2. Materials and methods 
The three mutant strains were originally obtained 
from the Jackson Laboratory (Bar Harbour, Maine, 
USA) and bred in our laboratory. The standard cere- 
brosides and sulphatides were purified from crudely 
dissected human brain white matter, and their com- 
position established as previously described [ 131 . 
PAPS was prepared enzymati~~Iy by the procedure 
of Robbins 114,151 and was separated from Na, 35S0, 
by descending chromatography. 
A 10% brain and kidney homogenate in 0,32 M 
sucrose containing 1 mM Na,EDTA and 3 mM 
Na,HPO, was centrifuged at 18,000 g for 20 min at 
2” in a Spinco model L centrifuge (rotor 30). The 
resulting supernatant was ~entrjfuged at 100,000 g 
for 60 min. The pellet obtained was suspended in the 
above sucrose solution containing 50% glycerol, to 
give a final concentration of about 5 mg of protein/ml, 
as determined by the method of Lowry et al. [ 161. 
This preparation was used as a source of enzyme. It 
could be kept unfrozen at -20” for at least 10 days 
without apparent loss of the enzyme activity. In some 
experiments a 10% whole brain homogenate was also 
used as a source of enzyme. 
The enzymic transfer of sulphate from 35S-PAP 
to endogenous galacto cerebrosides in a brain homo- 
91 
Volume 19, number 2 FEBS LETTERS December 1971 
genate was carried out by the method of Balasubra- 
manian and Bachhawat [ 171. PAPS-CST activity was 
assayed in the presence of 35S-PAP and exogenous 
galactocerebrosides with a biosynthetic system similar 
to the one described by M&harm and Ho [ 181. Un- 
treated microsomes were used as a source of enzyme 
instead of a deoxycholate solubilized microsomal pre- 
paration. Addition of ATP to the incubation medium 
resulted in a two-fold increase of incorporation of 
3sS into sulphatides from 35S-PAP. 
The appropriate amounts of cerebroside and deter- 
gent solutions in chloroform-methanol (2: 1, v/v) 
were mixed and dried in tubes before addition of 
other components in the incubation mixture. The 
reaction was stopped by addition of 2.5 ml chloro- 
form-methanol (2: 1, v/v) and thorough mixing on a 
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Fig. 1. In vitro formation of sulphatides from 35 S-PAP in lhe presence of exogenous galactocerebrosides by the PAPS-CST of 
normal and Jimpy mice as a function of enzyme concentration. Incubations were performed in a vol. of 0.5 ml containing: 0.120 
pmole of galactocerebrosides; 4 mg of BRIJ 96; 50 pmole of imidazole buffer (pH 7.0); 5 umole of ATP; 0.4 pmole of K,SO,; 
2.5 Mumole of KCI; 130,000-150,000 cpm of 35 S-PAP; and microsomal preparation, for 60 min at 37”. Assay of radioactivity and 
futher experimental details as given in the text. Each point is the average of data from 3 experiments. Vertical bars represent the 
range of values. 
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rubber-tipped mechanical agitator. Carrier sulphatides 
were added. The samples were centrifuged briefly. 
The upper aqueous phase and the interfacial protein 
layer were discarded, while the lower phase was washed 
twice with 1 ml of “theoretical upper phase” [ 191 
containing 0.88% potassium chloride to remove non- 
lipid contaminants. An aliquot of washed lower phase 
was dried in a counting vial. Scintillation fluid was 
added and the sample was counted in a liquid scintilla- 
tion spectrometer (ABAC SL40, Intertechnique, 
France). 
The labelled sulphatides were identified by sub- 
jecting the total lipid extract to thin-layer chromato- 
graphy on silica gel G (Merck) using 5 different solvant 
systems. After chromatographic development, the thin- 
layer plate was exposed to X-ray film (“Kodirex”, 
Kodak, France) for about 5 days, and the radioactive 
spots were identified by comparison with authentic 
sulphatides. 
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Fig. 2. Effect of the microsomal protein concentration on the PAPS-CST activity in normal and msd mice. The incubation system 
was similar to that described in fig. 1. Each point is the average of data from 3 experiments. Vertical bars represent he range of 
values. 
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3. Results and discussion 
As a first step, we have demonstrated the enzymic 
transfer of sulphate from 35S-PAP to endogenous 
galactocerebrosides in brain homogenates. In experi- 
ments carried out with brain homogenates of 19 day 
old animals, the PAPS-CST activity was strikingly 
decreased (7 to lo-fold) in Jimpy mice compared to 
controls. As a second step, the formation of sulphatides 
from radioactive PAPS was studied using free exo- 
genous galactocerebrosides as substrate. 
The addition of galactocerebrosides in-the incuba- 
tion system containing normal or mutant brain micro- 
somes increased the amount of synthesis of 35S- 
sulphatides 10 to 40-fold and even more, 32 to 52-fold 
with kidney microsomes. 
Radioautographs demonstrated 2 well-labelled reac- 
tion products (Rf 0.66 and 0.69 in the solvant system 
chloroform-methanol-2N ammonium hydroxide 
(60:35 :8, v/v), corresponding to phrenosine sulphate 
and Kerasine sulphate, respectively. More than 90% 
of the total lipid radioactivity was found in the two 
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Fig. 3. Effect of the microsomal protein concentration on the PAPS-CST activity in normal and Quaking mice. The ~cubation 
system was similar to that described in fig. 1, Each point is the average ofdata from 3 experiments. Vertical bars represent the 
range of values. 
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fractions. The brain microsomal sulphotransferase 
activities were strikingly decreased in all three mutants, 
4 to 7-fold in Jimpy (fig. I), 2-fold in msd (fig. 2) and 
Quaking (fig. 3), as were brain sulphatides ]2]. We 
assume that the observed decrease of sulphatide con- 
tent is the result of a deficient biosynthesis rather than 
an increased catabolism. The latter alternative is 
rendered unlikely by the results of Bowen and Radin 
[20] and by our own results showing that the total 
arylsulphatase activity at 20 days of postnatal age 
was unchanged in msd mutant as compared to control 
brains. Crossed incubations performed with the 
normal and mutant microsomal fractions gave no 
evidence of activation or inhibition effects. 
In normal mice, kidney PAPS-CST activity was 
about 2.5 times higher than in the brain. Using kidney 
microsomes as an enzyme source, no differences were 
found in PAPS-CST activity in any of the three 
mutants when compared to normal animals (figs. 1,2 
and 3). Therefore our findings suggest hat the genet- 
ically determined disorder is limited to the CNS in all 
three mutants. This is in contrast to human and canine 
Globoid (Krabbe) leucodystrophy (GLD), where 
PAPS-CST activity is reduced in the kidney, although 
not as markedly as in GLD brain [21] . 
The results of this study provide strong evidence 
that the decrease of sulphatide synthesis in the mutant 
brains is not secondary to the lack of cerebrosides 
available for sulphation, but results from a deficiency 
of the sulphotransferase activity. The observation that 
the deficiency of PAPS-CST activity is limited to the 
CNS, which is in accord with the results on other 
enzyme activities in mutant mice [7,22] , is of great 
interest considering the genetic control of enzyme 
biosynthesis. The data reported suggests an autonomic 
genetic control of enzyme synthesis in different cell 
types. 
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